Copyright
©The Author(s) 2023.
World J Clin Cases. Apr 6, 2023; 11(10): 2168-2180
Published online Apr 6, 2023. doi: 10.12998/wjcc.v11.i10.2168
Published online Apr 6, 2023. doi: 10.12998/wjcc.v11.i10.2168
mAb (s) | FDA EUA | Target on S | Omicron variant | |||
BA.1 | IC50 | BA.2 | IC50 | |||
Bamla/Etese | Yes | BRD or S | Reduction in activity vs control approximately 1000-fold (highly resistant) | > 10000 ng/mL | Reduction in activity vs control approximately 1000-fold (highly resistant) | > 10000 ng/mL |
Casir/Imdev | Yes | BRD | Reduction in activity vs control approximately 1000-fold (highly resistant) | > 10000 ng/mL | Reduction in activity vs control approximately 1000-fold (highly resistant) | > 10000 ng/mL |
Sotro | Yes | BRD | Median fold reduction in susceptibility 4.0 (IQR: 2.6 to 6.9) | Median 276 ng/mL (IQR: 163 to 423) | Median fold reduction in susceptibility 17 (IQR: 13 to 30) | Median 1250 ng/mL (IQR: 567 to 1456) |
Cilag/Tixag | Yes | BRD | Median fold reduction in susceptibility 86 (IQR:27 to 151). The FDA recommended that the dosage for each mAb in this combination be increased 300 mg and administered intramuscularly | Median 256 ng/mL (IQR: 170 to 750) | Median fold reduction in susceptibility 5.4 (IQR: 3.7 to 6.9). Nearly complete restoration BA.2 susceptibility to cilgavimab | Median 44 ng/mL (IQR: 27 to 73) |
Bebte | Yes | BRD | Median fold reduction in susceptibility 1.0 (IQR: 0.7 to 1.4) Bebtelovimab is the only mAb active against the current dominant circulating Omicron variant; in non- hospitalized adults, bebtelovimab may be used as an alternative therapy when no preferred therapy (e.g., nirmatrelvir/ritonavir, remdesivir) available | Median 2.6 ng/mL (IQR: 1.8 to 5.0) | Median fold reduction in susceptibility 1.0 (IQR: 0.7 to 1) | Median 4.0 ng/mL (IQR: 0.8 to 5.0) |
Regda | No | BRD | Displayed little residual activity | NA | Displayed little residual activity | NA |
Amuba | No | BRD | Displayed little residual activity | NA | Displayed little residual activity | NA |
Romlu | No | BRD | Retained partial activity | NA | Displayed little residual activity | NA |
Adint | No | BRD | Retained partial activity | NA | NA |
- Citation: Sun J, Yang ZD, Xie X, Li L, Zeng HS, Gong B, Xu JQ, Wu JH, Qu BB, Song GW. Clinical application of SARS-CoV-2 antibody detection and monoclonal antibody therapies against COVID-19. World J Clin Cases 2023; 11(10): 2168-2180
- URL: https://www.wjgnet.com/2307-8960/full/v11/i10/2168.htm
- DOI: https://dx.doi.org/10.12998/wjcc.v11.i10.2168